Douglas Carlson

Douglas Carlson is an accomplished executive in the biotechnology sector, currently serving as Chief Operating and Financial Officer at Avenge Bio since February 2022, focusing on innovative immunotherapeutic products for solid tumors. Prior to this role, Douglas held the same title at Ikena Oncology from January 2019 to February 2022, where responsibilities included overseeing finance and leading a successful $144 million IPO. Douglas has a rich background in corporate strategy and business development with previous positions at Collegium Pharmaceutical, BTG International, Lundbeck, and Ovation Pharmaceuticals, culminating in extensive expertise in healthcare private equity and investment banking from tenure at Pequot Ventures and Cowen & Co. Academically, Douglas holds a BA in American Studies with a concentration in Economics from Trinity College-Hartford and completed a post-graduate program in European Economics at the Oxford Advanced Study Program.